These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15353425)

  • 1. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure.
    Nichol G; Kaul P; Huszti E; Bridges JF
    Ann Intern Med; 2004 Sep; 141(5):343-51. PubMed ID: 15353425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summaries for patients. The cost-effectiveness of cardiac resynchronization therapy for heart failure.
    Ann Intern Med; 2004 Sep; 141(5):I29. PubMed ID: 15353442
    [No Abstract]   [Full Text] [Related]  

  • 3. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
    Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
    Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure.
    Woo CY; Strandberg EJ; Schmiegelow MD; Pitt AL; Hlatky MA; Owens DK; Goldhaber-Fiebert JD
    Ann Intern Med; 2015 Sep; 163(6):417-26. PubMed ID: 26301323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure.
    Mealing S; Woods B; Hawkins N; Cowie MR; Plummer CJ; Abraham WT; Beshai JF; Klein H; Sculpher M
    Heart; 2016 Nov; 102(21):1742-1749. PubMed ID: 27411837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.
    Aidelsburger P; Grabein K; Klauss V; Wasem J
    Clin Res Cardiol; 2008 Feb; 97(2):89-97. PubMed ID: 17955159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Quadripolar Versus Bipolar Left Ventricular Leads for Cardiac Resynchronization Defibrillator Therapy in a Large, Multicenter UK Registry.
    Behar JM; Chin HM; Fearn S; Ormerod JO; Gamble J; Foley PW; Bostock J; Claridge S; Jackson T; Sohal M; Antoniadis AP; Razavi R; Betts TR; Herring N; Rinaldi CA
    JACC Clin Electrophysiol; 2017 Feb; 3(2):107-116. PubMed ID: 28280785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
    Banz K;
    Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up.
    Gold MR; Padhiar A; Mealing S; Sidhu MK; Tsintzos SI; Abraham WT
    JACC Heart Fail; 2017 Mar; 5(3):204-212. PubMed ID: 28254126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK.
    Caro JJ; Guo S; Ward A; Chalil S; Malik F; Leyva F
    Curr Med Res Opin; 2006 Jun; 22(6):1171-9. PubMed ID: 16846550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector.
    Ribeiro RA; Stella SF; Camey SA; Zimerman LI; Pimentel M; Rohde LE; Polanczyk CA
    Value Health; 2010; 13(2):160-8. PubMed ID: 19725912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of defibrillation by targeted responders in public settings.
    Nichol G; Valenzuela T; Roe D; Clark L; Huszti E; Wells GA
    Circulation; 2003 Aug; 108(6):697-703. PubMed ID: 12900345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a risk-stratified approach to cardiac resynchronisation therapy defibrillators (high versus low) at the time of generator change.
    Claridge S; Sebag FA; Fearn S; Behar JM; Porter B; Jackson T; Sieniewicz B; Gould J; Webb J; Chen Z; O'Neill M; Gill J; Leclercq C; Rinaldi CA
    Heart; 2018 Mar; 104(5):416-422. PubMed ID: 28970277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of implantable cardiac devices in patients with systolic heart failure: a US perspective using real world data.
    Shah D; Lu X; Paly VF; Tsintzos SI; May DM
    J Med Econ; 2020 Jul; 23(7):690-697. PubMed ID: 32207659
    [No Abstract]   [Full Text] [Related]  

  • 18. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
    Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
    BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
    Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
    Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure.
    Chen L; Hay JW
    Cardiovasc Drugs Ther; 2004 Mar; 18(2):161-70. PubMed ID: 15162078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.